We searched The Cochrane Library and Medline for work published in the past 5 years (2005–10), as well as the abstracts of the American (American College of Rheumatology) and European (European League Against Rheumatism) congresses of Rheumatology published during the past 2 years (2009–10). We used the search terms “spondyloarthropathy”, “spondylarthropaty”, “spondyloarthritis”, “spondylarthritis”, “ankylosing spondylitis”, and “psoriatic arthritis”. We limited our search to published
SeriesSpondyloarthritis
Introduction
In 1974, Moll and colleagues1 established the concept of a group of inter-related disorders originally termed seronegative spondarthritides. The group of diseases now called spondyloarthritis consists of psoriatic arthritis, reactive arthritis, arthritis related to inflammatory bowel disease, a subgroup of juvenile idiopathic arthritis, and ankylosing spondylitis—the prototype of spondyloarthritis.2 The various clinical forms include spinal (axial) features, peripheral arthritis, enthesopathy, and extra-articular features such as uveitis, psoriasis, and inflammatory bowel disease. The clinical rationale for grouping these diseases is that they are simultaneously or sequentially identified in the same patient or in a family member. Furthermore, clinical characteristics such as eye involvement and enthesopathy are similar whatever the diagnosis.1, 2 A strong argument, based on work in animals, in favour of grouping these diseases is that HLA-B27 transgenic rats develop the various clinical features that are noted in human beings with spondyloarthritis.3
One subject of debate at present is whether the clinical approach, including diagnosis, classification, and management, should be focused on a specific disease subtype (eg, ankylosing spondylitis) or on the overall group of spondyloarthritis. In the 1970s, several sets of criteria were proposed to classify patients with a specific spondyloarthritis subtype, such as the modified New York criteria for ankylosing spondylitis.4 These criteria have important restrictions in clinical practice: they focus exclusively on the axial features, omitting the other clinical features of the disease. In 1990, Amor and colleagues5 proposed the first set of classification criteria for the entire group of spondyloarthritis, allowing a patient to be classified as having spondyloarthritis whatever the presenting symptoms. A different set of criteria for the entire group of spondyloarthritis was developed by the European Spondyloarhropathy Study Group,6 with inflammatory back pain and peripheral arthritis as major entry criteria. Recognition of the drawbacks of criteria focused on a specific subtype, the Assessment of Spondyloarthritis International Society (ASAS) did a large cross-sectional study to propose new criteria on the basis of the two main clinical features identified in daily practice—eg, axial symptoms and peripheral involvement.
In the first set of criteria focusing on patients presenting with axial symptoms (panel),7 the term axial spondyloarthritis was proposed for the entire range of axial diseases irrespective of structural damage. These criteria emphasise three important points: the relevance of the clinical features identified whatever the presenting symptoms, the value of new imaging techniques to detect sacroiliac changes, and the contribution of HLA-B27 typing.
One important advance is the use of MRI to assess sacroiliac changes. Plain radiographs can detect only structural changes such as joint erosion and subchondral-bone sclerosis seen at the late stage of the disease; this restriction is also the case for CT, although with higher sensitivity and specificity but greater exposure to radiation. Unfortunately, the medical term used to describe such chronic changes focuses on inflammation—eg, sacroiliitis—despite the fact that plain radiographs cannot detect inflammation. By contrast, MRI allows the visualisation of synovial fluid, synovitis within the sacroiliac joint, and subchondral-bone oedema. The relevant abnormalities detected with MRI have been described and clearly defined,8 allowing inclusion of active inflammatory lesions of sacroiliac joints with definite bone-marrow oedema and osteitis on MRI in the new criteria for axial spondyloarthritis.7 Whether such a definition—eg, MRI findings at the sacroiliac joints—is optimum remains an open question since data suggest that inflammatory lesions of the posterior structures of the spine as well as the spinal fatty Romanus lesions (fatty changes at vertebral corners) are also suggestive of spondyloarthritis.9, 10 More importantly, however, these criteria were developed in a well defined cross-sectional study population (eg, age <45 years and with back pain for at least 3 months) and have not yet been validated for diagnostic use in prospective studies in clinical practice.
The second set of criteria proposed by ASAS is focused on patients presenting with peripheral rheumatological involvement (eg, peripheral arthritis, enthesopathy, dactylitis) without axial symptoms.11 These criteria (figure 1) also emphasise the importance of the different clinical features, HLA-B27 typing, and imaging of sacroiliac joints despite the absence of spinal symptoms. Sacroiliac abnormalities at imaging raise the question of which of the investigations should be done when spondyloarthritis is suspected, whatever the presenting symptoms. Clinicians agree on the use of HLA-B27 typing, although it is only useful in cases with an a-priori high suspicion, and a negative result does not preclude the presence of spondyloarthritis. The findings of the study12 used to develop the criteria also suggest that in a case of peripheral rheumatological presentation, the systematic radiological (eg, plain radiographs and MRI) assessment of the sacroiliac joints might be of interest even in the absence of any axial features. Similarly, a systematic assessment of different entheses allows differentiation between spondyloarthritis patients and controls even in the absence of clinical enthesopathy.13, 14, 15
Enthesopathy, inflammation at the bone insertion sites of ligaments and tendons, is an important ASAS criterion. The main peripheral clinical location is the heel (inferior part at the insertion of plantar fascia on the calcaneus and posterior part at the insertion of Achilles tendon on the calcaneus). The recognition of spondyloarthritis and the use of these new criteria should allow clinical trials in patients with early disease and thereby the assessment of treatments to alter the course of the disease. Whether these criteria will also shorten the diagnostic delay remains to be investigated prospectively. Another interesting approach to reduce the diagnostic delay is the development of early referral strategies, since patients with back pain are usually first seen by primary care physicians.16 Defining better strategies and techniques for early diagnosis remains one of the major challenges in spondyloarthritis for the next decade.
Section snippets
Pathophysiology
Advances in the classification of spondyloarthritis show that progress in the understanding of genetics (eg, the gene for HLA-B27), the pathophysiology of inflammation (eg, lesions on MRI), and structural damage (eg, sacroiliitis on plain radiographs) affect clinical practice in the context of classification and diagnosis. Basic understanding of the pathophysiology of the disease is even more relevant for outcome measurement and targeted treatment.
Through familial aggregation studies17
Outcome assessment
The optimum management of patients necessitates systematically addressing five points related to the possible clinical presentations (axial, peripheral, enthesopathy, and extra-articular): does the patient really have the disease, is the disease active, is the disease severe, is the disease potentially severe, and is the disease refractory? One of the major challenges in spondyloarthritis remains the development of sensitive and specific imaging or biological markers for early diagnosis.
Treatment
The objectives of treatment of spondyloarthritis are to improve the condition of the patient (eg, pain, functional disability) as well as to prevent subsequent clinical deterioration. ASAS has provided recommendations for both the management of spondyloarthritis in general90 and the use of TNF blockers in particular.92
A recent Cochrane systematic review of published work93 concluded that an individual home-based or supervised exercise programme is better than no intervention, that supervised
Future prospects
From the present state of the art in spondyloarthritis, several important clinical and pathophysiological issues seem unsolved: the development and validation of better clinical or biological markers for early diagnosis and for prognosis, clarification whether the subtypes of spondyloarthritis are driven by different pathophysiological processes or rather represent different phenotypes of a single pathological entity, deciphering the functional role and the interaction of genes emerging from
Search strategy and selection criteria
References (131)
- et al.
Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: An animal model of HLA-B27-associated human disorders
Cell
(1990) - et al.
HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis
Lancet
(1993) - et al.
HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum
J Biol Chem
(2002) - et al.
MR Imaging of the spine and sacroiliac joints in ankylosing spondylitis
J Radiol
(2010) - et al.
Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome
Medicine (Baltimore)
(1974) - et al.
Spondyloarthritis: pathogenesis, clinical aspects and diagnosis
- et al.
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria
Arthritis Rheum
(1984) - et al.
Criteria of the classification of spondylarthropathies
Rev Rhum Mal Osteoart
(1990) - et al.
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
Arthritis Rheum
(1991) - et al.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Ann Rheum Dis
(2009)
Defining active sacroiliitis on Magnetic Resonance Imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI Group
Ann Rheum Dis
Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine
Rheumatology
The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy
Ann Rheum Dis
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
Ann Rheum Dis
New ASAS classification criteria for peripheral spondyloarthritis
Ann Rheum Dis
How to evaluate and improve the reliability of power Doppler ultrasonography for assessing enthesitis in spondyloarthritis
Arthritis Rheum
Validity of enthesis ultrasound assessment in spondyloarthropathy
Ann Rheum Dis
Enthesis inflammation in recurrent acute anterior uveitis without spondyloarthritis
Arthritis Rheum
Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis
Ann Rheum Dis
Genetics and genomics in ankylosing spondylitis
Immunol Rev
Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins
J Biol Chem
Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis
Ann Rheum Dis
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
Nat Genet
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci
Nat Genet
Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis
Ann Rheum Dis
The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (TRADD)
Ann Rheum Dis
Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis
PLoS Genet
Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene
Genes Immun
Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy
Arthritis Rheum
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats
J Exp Med
Additional human β2-microglobulin curbs HLA–B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA–B27–transgenic rats
Arthritis Rheum
HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis
Arthritis Rheum
CD8αβ T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats
J Immunol
Spondylarthritis in HLA–B27/human β2-microglobulin–transgenic rats is not prevented by lack of CD8
Arthritis Rheum
HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors
J Immunol
Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis
Arthritis Rheum
Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies
J Immunol
HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response
J Immunol
Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-β induction via X-box binding protein 1
Eur J Immunol
HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats
Arthritis Rheum
Tumor necrosis factor α blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and toll-like receptor 4 in spondylarthropathy
Arthritis Rheum
Toll-like receptor 2 variants are associated with acute reactive arthritis
Arthritis Rheum
The concept of a ‘synovio-entheseal complex’ and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond
Arthritis Rheum
Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy
J Pathol
Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy
Arthritis Res Ther
A proposed classification of the immunological diseases
PLoS Med
Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases
J Exp Med
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis
Arthritis Rheum
Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor α
Arthritis Rheum
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
Arthritis Rheum
Cited by (646)
Nod-like receptors in inflammatory arthritis
2024, Biomedical JournalCharacteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
2023, Seminars in Arthritis and RheumatismT cells in the pathogenesis of axial spondyloarthritis
2023, Joint Bone Spine